An earlier study has demonstrated that VEGF targeting therapy leads to the shrinkage of the primary tumor, but increases intratumoral hypoxia, resulting in a higher rate of detachment of the circulating tumor cell (CTC) cluster and metastasis formation. This evidence concerns the gene VEGFA and neoplasm.